Literature DB >> 12509809

Suppression of activated microglia promotes survival and function of transplanted oligodendroglial progenitors.

Su-Chun Zhang1, Brian D Goetz, Ian D Duncan.   

Abstract

To evaluate the functional consequence of microglial activation in vivo, oligodendroglial progenitors were transplanted into the spinal cord of Long Evans shaker, a myelin mutant rat in which myelin defects are associated with progressive microglial activation. Cells grafted into neonatal rats at the initiation of gliosis successfully myelinated axons. However, cells transplanted during peak microglial activation did not lead to myelination due to death of the grafted cells within 3 days after transplantation. Pretreatment of these animals with minocycline, a tetracycline derivative, resulted in cell survival and myelination by the grafted cells. In culture, minocycline did not affect the survival, proliferation, or differentiation of oligodendroglial progenitors. Hence, minocycline likely modulates the function of reactive glia in vivo to promote the survival and myelination of transplanted oligodendroglial progenitors. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12509809     DOI: 10.1002/glia.10172

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  14 in total

Review 1.  Cellular transplantation strategies for spinal cord injury and translational neurobiology.

Authors:  Paul J Reier
Journal:  NeuroRx       Date:  2004-10

Review 2.  Prospects for neural stem cell-based therapies for neurological diseases.

Authors:  Jaime Imitola
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 3.  Current challenges for the advancement of neural stem cell biology and transplantation research.

Authors:  Kristien Reekmans; Jelle Praet; Jasmijn Daans; Veerle Reumers; Patrick Pauwels; Annemie Van der Linden; Zwi N Berneman; Peter Ponsaerts
Journal:  Stem Cell Rev Rep       Date:  2012-03       Impact factor: 5.739

4.  Cellular compensatory mechanisms in the CNS of dysmyelinated rats.

Authors:  Jacek M Kwiecien
Journal:  Comp Med       Date:  2010-06       Impact factor: 0.982

5.  Reversible neural stem cell niche dysfunction in a model of multiple sclerosis.

Authors:  Stine Rasmussen; Jaime Imitola; Angel Ayuso-Sacido; Yue Wang; Sarah C Starossom; Pia Kivisäkk; Bing Zhu; Morten Meyer; Roderick T Bronson; Jose Manuel Garcia-Verdugo; Samia J Khoury
Journal:  Ann Neurol       Date:  2011-03-09       Impact factor: 10.422

6.  Blueberry supplementation attenuates microglial activation in hippocampal intraocular grafts to aged hosts.

Authors:  Lauren M Willis; Linnea Freeman; Paula C Bickford; E Matthew Quintero; Claudia D Umphlet; Alfred B Moore; Laura Goetzl; Ann-Charlotte Granholm
Journal:  Glia       Date:  2010-04-15       Impact factor: 7.452

7.  A novel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia.

Authors:  Qiusheng Si; Melissa Cosenza; Mee-Ohk Kim; Meng-Liang Zhao; Michael Brownlee; Harris Goldstein; Sunhee Lee
Journal:  J Neurovirol       Date:  2004-10       Impact factor: 2.643

Review 8.  Human embryonic stem cells: a potential source of transplantable neural progenitor cells.

Authors:  Daniel J Guillaume; Su-Chun Zhang
Journal:  Neurosurg Focus       Date:  2008       Impact factor: 4.047

9.  A novel role for Sema3A in neuroprotection from injury mediated by activated microglia.

Authors:  Henry H Majed; Siddharthan Chandran; Simone P Niclou; Richard S Nicholas; Alastair Wilkins; Mark G Wing; Kate E Rhodes; Maria Grazia Spillantini; Alastair Compston
Journal:  J Neurosci       Date:  2006-02-08       Impact factor: 6.167

10.  Minocycline treatment following hypoxic/ischaemic injury attenuates white matter injury in a rodent model of periventricular leucomalacia.

Authors:  M Lechpammer; S M Manning; F Samonte; J Nelligan; E Sabo; D M Talos; J J Volpe; F E Jensen
Journal:  Neuropathol Appl Neurobiol       Date:  2008-01-22       Impact factor: 8.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.